| Literature DB >> 28330507 |
Mathilde Adsersen1, Lau Caspar Thygesen2, Anders Bonde Jensen3, Mette Asbjoern Neergaard4, Per Sjøgren5, Mogens Groenvold6,7.
Abstract
BACKGROUND: Specialised palliative care (SPC) takes place in specialised services for patients with complex symptoms and problems. Little is known about what determines the admission of patients to SPC and whether there are differences in relation to institution type. The aims of the study were to investigate whether cancer patients' admittance to SPC in Denmark varied in relation to sex, age and diagnosis, and whether the patterns differed by type of institution (hospital-based palliative care team/unit, hospice, or both).Entities:
Keywords: Admittance; Cancer; End of life care; Hospice; Palliative care team; Specialised palliative care
Mesh:
Year: 2017 PMID: 28330507 PMCID: PMC5363002 DOI: 10.1186/s12904-017-0194-z
Source DB: PubMed Journal: BMC Palliat Care ISSN: 1472-684X Impact factor: 3.234
The characteristics of the study population overall and institution type specific admittance
| N | Overall admittance to SPC | Admittance to hospital-based palliative care team/unit | Admittance to Hospice | Admittance to both hospital-based palliative care team/unit and hospice | |
|---|---|---|---|---|---|
| (%) | % | % | % | % | |
| All cancer diagnoses | 44,548 (100) | 37.4 | 26.8 | 17.3 | 6.8 |
| Sex | |||||
| Men | 23,312 (52.3) | 35.5 | 26.8 | 14.7 | 6.0 |
| Women | 21,236 (47.7) | 39.5 | 26.8 | 20.2 | 7.8 |
| Age (years) | |||||
| 18–39 | 406 (0.9) | 65.0 | 52.2 | 30.5 | 17.7 |
| 40–49 | 1,353 (3.0) | 59.7 | 46.3 | 29.3 | 16.0 |
| 50–59 | 4,521 (10.2) | 51.1 | 39.2 | 22.8 | 10.8 |
| 60–69 | 11,221 (25.2) | 44.3 | 32.5 | 20.3 | 8.5 |
| 70–79 | 13,870 (31.1) | 36.7 | 25.9 | 16.9 | 6.1 |
| 80+ | 13,177 (29.6) | 24.3 | 15.9 | 11.7 | 3.3 |
| Diagnosis (cancer site) | |||||
| Oral cavity, nasopharyngeal (etc.) (C00-C14) | 998 (2.2) | 37.7 | 30.0 | 16.2 | 8.5 |
| Oesophageal (C15) | 1,101 (2.5) | 43.0 | 32.5 | 17.3 | 6.8 |
| Stomach (C16) | 1,285 (2.9) | 47.6 | 35.4 | 22.0 | 9.9 |
| Small intestine (C17) | 162 (0.4) | 40.1 | 30.9 | 17.3 | 8.0 |
| Colorectal (C18–C20) | 5,649 (12.7) | 36.0 | 25.9 | 16.7 | 6.6 |
| Liver (etc.) (C22) | 845 (1.9) | 34.7 | 24.6 | 14.0 | 3.9 |
| Pancreatic (C25) | 2,473 (5.6) | 49.4 | 34.9 | 22.6 | 8.1 |
| Laryngeal (C32) | 280 (0.6) | 29.6 | 22.5 | 12.9 | 5.7 |
| Tracheal, bronchial and lung (C33–C34) | 10,338 (23.2) | 39.5 | 28.2 | 18.4 | 7.1 |
| Melanoma skin cancer (C43) | 774 (1.7) | 45.1 | 31.7 | 23.1 | 9.7 |
| Sarcoma (C46–C49) | 326 (0.7) | 54.9 | 40.8 | 25.8 | 11.7 |
| Breast (C50) | 3,618 (8.1) | 37.3 | 25.9 | 18.3 | 6.9 |
| Cervical (C53) | 301 (0.7) | 45.2 | 31.6 | 26.3 | 12.6 |
| Uterine (C54–55) | 499 (1.1) | 42.1 | 29.1 | 20.2 | 7.2 |
| Ovarian (etc.) (C56,C570–C574) | 1,109 (2.5) | 49.9 | 33.3 | 27.7 | 11.1 |
| Prostate (C61) | 3,512 (7.9) | 33.9 | 27.7 | 12.6 | 6.4 |
| Testicular (C62) | 39 (0.1) | 30.8 | 28.2 | 12.8 | 10.3 |
| Kidney (etc.) (C64–C66) | 991 (2.2) | 44.4 | 33.5 | 18.8 | 7.9 |
| Bladder (C67) | 1,378 (3.1) | 32.3 | 24.2 | 13.4 | 5.4 |
| Brain/central nervous system (C70–C71, C751–C753)a | 1,407 (3.2) | 40.9 | 26.0 | 22.3 | 7.4 |
| Thyroid (C73) | 114 (0.3) | 45.6 | 32.5 | 21.1 | 7.9 |
| Unknown primary cancer (C76–C80) | 1,802 (4.1) | 32.4 | 21.6 | 15.8 | 5.1 |
| Hodgkin disease (C81) | 58 (0.1) | 19.0 | 13.8 | 10.3 | 5.2 |
| Non-Hodgkin lymphoma (C82-C85) | 814 (1.8) | 20.2 | 11.7 | 11.4 | 3.0 |
| Multiple myeloma (C 90) | 635 (1.4) | 20.6 | 14.0 | 9.3 | 2.7 |
| Leukemia (C91–C95) | 1,200 (2.7) | 15.3 | 8.4 | 7.9 | 1.1 |
| Other cancer (all other C codes) | 2,840 (6.4) | 29.9 | 21.4 | 13.8 | 5.3 |
aIncluding the following D-codes: D32, D42, D330–332, D352–354, D430–432, D443–445, D333–339 and D433–439
Fig. 1Flow-chart for sampling the study population
Overall and institution type specific odds of admittance to SPC for Danish cancer patients, mutually adjusted
| Overall admittance to SPC | Admittance to hospital-based palliative care team/unit | Admittance to hospice | Admittance to both hospital-based palliative care team/unit and hospice | |
|---|---|---|---|---|
| OR (95% CI) | OR (95% CI) | OR (95% CI) | OR (95% CI) | |
| Sex | ( | ( | ( | ( |
| Women | 1.23 (1.17–1.28) | 1.06 (1.00–1.11) | 1.45 (1.37–1.54) | 1.34 (1.23–1.47) |
| Men | 1 (ref) | 1 (ref) | 1 (ref) | 1 (ref) |
| Age (years) | ( | ( | ( | ( |
| 18–39 | 6.44 (5.19–7.99) | 6.81 (5.53–8.38) | 3.17 (2.54–3.97) | 6.73 (5.08–8.93) |
| 40–49 | 4.60 (4.09–5.18) | 4.80 (4.26–5.41) | 2.90 (2.54–3.31) | 5.64 (4.72–6.74) |
| 50–59 | 3.22 (3.00–3.47) | 3.48 (3.22–3.76) | 2.13 (1.94–2.32) | 3.63 (3.16–4.17) |
| 60–69 | 2.46 (2.32–2.60) | 2.56 (2.41–2.73) | 1.89 (1.76–2.03) | 2.80 (2.49–3.16) |
| 70–79 | 1.80 (1.70–1.89) | 1.86 (1.75–1.97) | 1.52 (1.42–1.64) | 1.97 (1.74–2.22) |
| 80+ | 1 (ref) | 1 (ref) | 1 (ref) | 1 (ref) |
| Diagnosis (cancer site) | ( | ( | ( | ( |
| Oral cavity, nasopharyngeal (etc.) (C00–C14) | 0.95 (0.83–1.09) | 1.07 (0.93–1.23) | 0.94 (0.79–1.12) | 1.23 (0.97–1.55) |
| Oesophageal (C15) | 1.34 (1.18–1.52) | 1.36 (1.19–1.56) | 1.09 (0.93–1.29) | 1.08 (0.85–1.38) |
| Stomach (C16) | 1.69 (1.50–1.90) | 1.63 (1.44–1.85) | 1.50 (1.30–1.73) | 1.67 (1.37–2.04) |
| Small intestine (C17) | 1.23 (0.89–1.68) | 1.34 (0.96–1.87) | 1.07 (0.72–1.59) | 1.31 (0.75–2.29) |
| Colorectal (C18–C20) | 1.13 (1.05–1.22) | 1.16 (1.07–1.26) | 1.09 (0.99–1.19) | 1.18 (1.03–1.35) |
| Liver (etc.) (C22) | 0.92 (0.80–1.07) | 0.91 (0.77–1.07) | 0.83 (0.68–1.02) | 0.59 (0.42–0.84) |
| Pancreatic (C25) | 1.77 (1.61–1.94) | 1.59 (1.44–1.75) | 1.47 (1.31–1.64) | 1.31 (1.11–1.54) |
| Laryngeal (C32) | 0.75 (0.58–0.97) | 0.82 (0.62–1.08) | 0.80 (0.57–1.13) | 0.93 (0.57–1.53) |
| Tracheal, bronchial and lung (C33–C34) | 1.16 (1.09–1.23) | 1.15 (1.07–1.23) | 1.12 (1.03–1.21) | 1.12 (1.00–1.25) |
| Melanoma skin cancer (C43) | 1.46 (1.26–1.69) | 1.31 (1.12–1.54) | 1.52 (1.28–1.81) | 1.53 (1.19–1.96) |
| Sarcoma (C46–C49) | 1.90 (1.52–2.38) | 1.74 (1.39–2.19) | 1.54 (1.20–1.98) | 1.58 (1.12–2.23) |
| Breast (C50) | 0.96 (0.88–1.05) | 0.99 (0.90–1.09) | 0.94 (0.84–1.04) | 0.93 (0.79–1.08) |
| Cervical (C53) | 1.10 (0.87–1.39) | 1.06 (0.83–1.36) | 1.30 (1.00–1.69) | 1.43 (1.01–2.03) |
| Uterine (C54–55) | 1.35 (1.13–1.62) | 1.36 (1.11–1.66) | 1.16 (0.93–1.45) | 1.15 (0.82–1.62) |
| Ovarian (etc.) (C56,C570–C574) | 1.57 (1.38–1.78) | 1.38 (1.20–1.58) | 1.56 (1.35–1.80) | 1.52 (1.23–1.86) |
| Prostate (C61) | 1.32 (1.21–1.44) | 1.54 (1.40–1.69) | 1.04 (0.93–1.18) | 1.58 (1.34–1.87) |
| Testicular (C62) | 0.50 (0.26–0.99) | 0.68 (0.34–1.37) | 0.63 (0.25–1.56) | 1.11 (0.40–3.06) |
| Kidney (etc.) (C64–C66) | 1.46 (1.28–1.66) | 1.49 (1.30–1.71) | 1.19 (1.01–1.40) | 1.28 (1.01–1.63) |
| Bladder (C67) | 1.04 (0.92–1.17) | 1.13 (0.99–1.29) | 0.92 (0.78–1.08) | 1.06 (0.83–1.35) |
| Brain/CNS (C70–C71, C751–C753)a | 1.05 (0.98–1.17) | 0.85 (0.75–0.97) | 1.30 (1.13–1.49) | 0.97 (0.78–1.20) |
| Thyroid (C73) | 1.54 (1.07–2.22) | 1.49 (1.01–2.20) | 1.29 (0.83–2.00) | 1.25 (0.64–2.43) |
| Unknown primary cancer (C76–C80) | 0.93 (0.83–1.04) | 0.89 (0.79–1.00) | 0.99 (0.86–1.13) | 0.86 (0.69–1.07) |
| Hodgkin disease (C81) | 0.33 (0.17–0.63) | 0.37 (0.18–0.77) | 0.52 (0.23–1.17) | 0.65 (0.21–2.03) |
| Non-Hodgkin lymphoma (C82–C85) | 0.49 (0.42–0.60) | 0.41 (0.33–0.51) | 0.70 (0.56–0.87) | 0.50 (0.33–0.74) |
| Multiple myeloma (C 90) | 0.50 (0.42–0.61) | 0.52 (0.42–0.65) | 0.55 (0.42–0.72) | 0.46 (0.28–0.73) |
| Leukemia (C91–C95) | 0.34 (0.29–0.40) | 0.29 (0.23–0.35) | 0.47 (0.38–0.58) | 0.18 (0.10–0.30) |
| Other cancer (all other C codes) | 0.91 (0.83–1.00) | 0.96 (0.87–1.07) | 0.90 (0,80–1,02) | 0.99 (0,83–1,19) |
| Average of all diagnoses | 1 (ref) | 1 (ref) | 1 (ref) | 1 (ref) |
aIncluding the following D-codes: D32, D42, D330–332, D352–354, D430–432, D443–445, D333–339 and D433–439